Genmab A/S
GMAB.CO
NASDAQ Copenhagen1,810.50
DKK
-58.00
- -
Genmab A/S
GMAB.CO
(NASDAQ Copenhagen)
Recent
price
1,810.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Genmab A/S is a Danish biotechnology company that creates, develops and commercializes differentiated antibody therapeutics focused on oncology and other serious diseases; its core offerings include proprietary technologies such as DuoBody, HexaBody, DuoHexaBody and HexElect for bispecific and multispecific antibodies, alongside marketed products like EPKINLY (epcoritamab, a CD3xCD20 bispecific for relapsed/refractory diffuse large B-cell lymphoma, partnered 50:50 with AbbVie), Tivdak (tisotumab vedotin, a tissue factor-directed antibody-drug conjugate for recurrent or metastatic cervical cancer, partnered 50:50 with Seagen), and royalty-generating partnered medicines including DARZALEX/DARZALEX Faspro (daratumumab for multiple myeloma and AL amyloidosis, Janssen), Kesimpta (ofatumumab for relapsing remitting multiple sclerosis, Novartis), Rybrevant (amivantamab for non-small cell lung cancer, Janssen), Talvey (talquetamab for relapsed/refractory multiple myeloma, Janssen), Tecvayli (teclistamab for relapsed/refractory multiple myeloma, Janssen) and Tepezza (teprotumumab for thyroid eye disease, Horizon); the company maintains a robust pipeline encompassing late-stage programs for epcoritamab in follicular lymphoma and chronic lymphocytic leukemia, tisotumab vedotin expansions in solid tumors, and others like acasunlimab and tecaginlimab targeting PD-L1x4-1BB and CD40x4-1BB respectively. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab operates globally through subsidiaries in the Netherlands (Genmab B.V., Utrecht), the United States (Genmab U.S., Inc., Princeton, New Jersey), Japan (Genmab K.K., Tokyo), Germany (Genmab Germany GmbH, Munich) and China (Genmab (Suzhou) Co., Ltd.), with affiliates supporting research, development and commercialization across North America, Europe and Asia Pacific. Recent major developments include the April 2024 acquisition of ProfoundBio for $1.8 billion to expand its antibody-drug conjugate capabilities and oncology portfolio, followed by the September 2025 announcement of an $8.0 billion all-cash acquisition of Merus N.V. (expected to close in early Q1 2026), adding the late-stage petosemtamab (a bispecific antibody with Breakthrough Therapy Designations for head and neck cancer) to accelerate Genmab's shift toward a wholly owned commercial model; these transactions, funded via cash and $5.5 billion in debt financing from Morgan Stanley, enhance late-stage pipeline diversity and project multiple proprietary launches by 2027, alongside 2025 revenue guidance of $3.5-3.7 billion driven by royalty growth from DARZALEX and independent EPKINLY/Tivdak sales expansions in Europe and Japan.